Expression of interleukin-22/STAT3 signaling pathway in ulcerative colitis and related carcinogenesis

Table 1 Clinical characteristics of ulcerative colitis patients

	Normal control n = 20	Histological activity of UC			Types of UC		UC with dysplasia n = 10
		Inactive n = 10	Mild-moderate n = 30	Severe n = 34	Initial n = 30	Chronic n = 44
Gender (n)
Male	14	5	16	22	16	27	6
Female	6	5	14	12	14	17	4
Mean age3, yr	40.6 ± 12.5	41.2 ± 13.3	44.7 ± 13.2	43.2 ± 17.1	42.8 ± 17.3	46.5 ± 13.6	44.7 ± 16.6
Mean duration of disease3, yr	-	6.14 ± 4.2	4.3 ± 2.3	3.7 ± 3.1	0.8 ± 0.6	5.1 ± 0.61	10.5 ± 1.42
Extent of disease (n)
Extensive colitis	-	0	8	19	8	19	3
Left-side colitis	-	4	13	9	13	13	4
Proctitis	-	6	9	6	9	12	3
Treatment (n)
Aminosalicylates	-	8	25	20	16	35	5
Corticosteroids	-	4	5	18	4	15	3
Immunosuppressive agent	-	0	0	1	0	1	0
Biological agent	-	0	0	0	0	0	0
None	-	3	2	0	10	5	2

¹The mean duration of disease in the chronic group (5.1 ± 0.6 years) was significantly longer than in the initial group (0.8 ± 0.6 years; P < 0.001);

²The mean duration of disease in the ulcerative colitis (UC) with dysplasia group (10.5 ± 1.4 years) was significantly longer than in other groups (P < 0.05);

³Data are expressed as mean ± SD.